Q-linea: Initial take on Q1 2023 - Redeye

Q-linea is in a transition period after the break with Thermo Fisher and in Q1 there is no reported sales. Q-linea has decided on a cost saving program and the company has a targeted regional sales strategy in Europe. Q-linea points to an UK order of the ASTar units from the UK partner Pro-Lab Diagnostics which is positive for the 2023 outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/902148/q-linea-initial-take-on-q1-2023?utm_source=finwire&utm_medium=RSS